US stock market crash: S&P 500, Dow Jones, Nasdaq crash at U.S Stock Market. Top gaining, losing stocks at Wall Street

Among the 11 major sectors of the S&P 500, financials fell the most, while consumer staples made the biggest percentage gain. The health index rose on a boost from Eli Lilly after rival Novo Nordisk’s obesity drug CagriSema underperformed Eli Lilly’s drug Zepbound in a head-to-head trial. Domino’s Pizza, among other movers, also rose after the fast-food chain’s fourth-quarter same-store sales beat Wall Street forecasts. PayPal jumped following a Bloomberg report that the payments firm had attracted takeover interest.
Big losses on Wall Street hit companies under suspicion of being undermined by AI-powered rivals. Investors have been punishing the shares of such companies harshly and abruptly lately.
CrowdStrike fell 9.8 percent, bringing its first-year loss to 25.3 percent. A new tool from Anthropic that scans codebases for vulnerabilities and recommends targeted software patches for human review is hitting stocks in the cybersecurity industry.
AppLovin lost 9.1 percent of its value, bringing its year-to-date loss to 43.5 percent. It is among software companies hurt by concerns that AI competition will steal customers and fundamentally reset their industries.
Companies that lend money to software companies whose revenues may be threatened also continued to fall, with Blue Owl Capital falling 3.4 percent, bringing its loss for the year so far to 30.1 percent.
Bigger moves may be in store for Wall Street this week, especially with Nvidia’s earnings report due on Wednesday. There are growing concerns that companies like Alphabet and Amazon are spending so much on Nvidia’s chips that they may never recoup their investments with higher productivity and future profits.
Elsewhere on Wall Street, airline stocks fell after heavy snowfall and high winds canceled thousands of flights in the busy Northeast.
United Airlines lost 5.2 percent, American Airlines lost 4.9 percent and Delta Air Lines lost 3.7 percent.
U.S.-traded shares of Novo Nordisk tumbled 16.4 percent after the Danish drugmaker said a trial of its CagriSema drug showed people lost a smaller percentage of their weight after 84 weeks compared with a similar drug made by rival Eli Lilly. Eli Lilly rose 4.9 percent.



